A Mab A Case Study In Bioprocess Development ((install)) Page

The case study "A-Mab: A Case Study in Bioprocess Development" is a landmark document in the pharmaceutical industry, created by the CMC Biotech Working Group (including experts from Abbott, Amgen, Genentech, and Pfizer). It serves as a comprehensive educational tool to demonstrate how Quality by Design (QbD) principles from ICH Q8(R2), Q9, and Q10 can be applied to the complex lifecycle of a monoclonal antibody (mAb). Core Framework and Objectives

6. Downstream Purification

6.1 Capture Step

• Protein A affinity chromatography: resin selection (ligand type, leachables, alkali-stability), residence time, loading density, elution conditions.
• High-throughput resin screening for dynamic binding capacity (DBC), selectivity.
• Viral inactivation (low pH hold) typically integrated post-protein A.

14. Case Study — End-to-End Example (Illustrative)

• Molecule: IgG1 with moderate aggregation tendency, glycosylation requiring high G0F content.
• Chosen platform: CHO-S stable clone, fed-batch process targeting 6 g/L titer via optimized feed, 14-day run.
• Downstream: Protein A capture (milligram per mL DBC optimized), CEX polishing to remove basic variants, AEX flow-through for HCP clearance, nanofiltration for viral removal, final formulation 150 mg/mL in histidine/sucrose/polysorbate.
• Key outcomes: overall recovery 55–65%, aggregate <1%, HCP <100 ppm, projected COGs $50–150/g (illustrative).
• Process risks and mitigations: proteolysis controlled by low temperature harvest; methionine oxidation minimized by antioxidant addition; resin leachables handled by robust cleaning and analytics.

A Mab: A Case Study in Bioprocess Development

1. Introduction: The Therapeutic Target

Product: A humanized IgG1 monoclonal antibody (mAb) targeting the immune checkpoint protein PD-L1, indicated for solid tumors. Challenge: The original lead candidate, produced in murine ascites, had low productivity (0.2 g/L) and high immunogenicity risk. The goal: develop a scalable, GMP-compliant process for Phase I clinical trials with a target titer >3 g/L and ≥95% purity. A Mab A Case Study In Bioprocess Development

To overcome these limitations, a comprehensive optimization program was implemented, focusing on: The case study "A-Mab: A Case Study in